scholarly journals Prognostic significance of primary tumour volume in nasopharyngeal carcinoma – a single institute study

2019 ◽  
Vol 7 (1) ◽  
pp. 24-29
Author(s):  
Dr. S.D. Shamsundar ◽  
◽  
Dr. Jagannath K.P. ◽  
Dr. Niveditha S. ◽  
Dr. K. Aradhana ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Tumour ◽  
Prognostic Significance ◽  
Tumour Volume

Primary Tumour Volume Delineation in Nasopharyngeal Carcinoma and Correlation with 1997 AJCC Tumour Stage Classification

2001 ◽  
Vol 30 (04) ◽  
pp. 231 ◽  
Author(s):  
Cheng-Chuan Chang ◽  
Mu-Kuan Chen ◽  
Mu-Tai Liu ◽  
Yung-Sung Wen ◽  
Hwa-Koon Wu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Tumour ◽  
Tumour Volume ◽  
Tumour Stage ◽  
Volume Delineation ◽  
Stage Classification

Prognostic significance of endoluminal ultrasound defined tumor volume (EDTV) in patients diagnosed with esophageal cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15519-e15519
Author(s):  
X. Escofet ◽  
C. Twine ◽  
A. Roberts ◽  
B. Dave ◽  
C. Rawlinson ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Primary Tumour ◽  
Multidisciplinary Treatment ◽  
Prognostic Significance ◽  
Palliative Therapy ◽  
Prognostic Indicator ◽  
Tumour Volume ◽  
Endoluminal Ultrasound ◽  
Tumour Length ◽  
N Stage

e15519 Background: The aim of this study was to assess the prognostic significance of endoluminal ultrasound defined tumour volume (EDTV) in patients diagnosed with esophageal cancer. The hypothesis was that tumour volume is a better predictor of outcome than tumour length. Methods: One hundred and seventy-four consecutive patients (median age 64y, 128 m) underwent both CT and specialist EUS, and the maximum potential tumour cylinder volume (EDTV) was calculated using the formula πr2L (cylinder volume), where r = tumour thickness (cm) and L = total length of disease, including the position and level of both the primary tumour and proximal and distal lymph nodes (cm). All patients received stage directed multidisciplinary treatment [surgery 104 patients (80 neoadjuvant chemotherapy), definitive chemoradiotherapy 54 patients, and palliative therapy alone 16 patients]. The primary measure of outcome was survival. Results: Survival was related to EUS T (p=0.013), EUS N (p=0.001), EUS M1a stage (p=0.004), EUS disease length (p=0.001), and EDTV (all patients <25cm3, p=0.001, surgical patients <40cm3, p=0.036). Forward conditional multivariate analysis revealed 3 factors to be associated with survival; EUS N stage (HR= 1.646, 95% CI 1.041 to 2.602, p=0.033), EUS M1a stage (HR= 2.702, 95% CI 1.069 to 6.830, p=0.036), and EDTV (HR= 2.702, 95% CI 1.069 to 6.830, p=0.025). Conclusions: EDTV emerged as a new and important prognostic indicator for patients diagnosed with esophageal cancer. No significant financial relationships to disclose.

Expression of p53 Protein and Primary Tumour Volume in Patients with Nasopharyngeal Carcinoma

2004 ◽  
Vol 33 (05) ◽  
pp. 304 ◽  
Author(s):  
Mu-Kuan Chen ◽  
Hong-Shen Lee ◽  
Julia H. Chang ◽  
Cheng-Chuan Chang
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
P53 Protein ◽  
Primary Tumour ◽  
Tumour Volume

scholarly journals A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease

2021 ◽  
Author(s):  
Mari K. Halle ◽  
Marte Sødal ◽  
David Forsse ◽  
Hilde Engerud ◽  
Kathrine Woie ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Primary Tumour ◽  
Treatment Options ◽  
Prognostic Significance ◽  
Gene Signature ◽  
Prognostic Impact ◽  
Cancer Disease ◽  
Gene Set ◽  
Patient Cohort ◽  
Protein Levels

Abstract Background Advanced cervical cancer carries a particularly poor prognosis, and few treatment options exist. Identification of effective molecular markers is vital to improve the individualisation of treatment. We investigated transcriptional data from cervical carcinomas related to patient survival and recurrence to identify potential molecular drivers for aggressive disease. Methods Primary tumour RNA-sequencing profiles from 20 patients with recurrence and 53 patients with cured disease were compared. Protein levels and prognostic impact for selected markers were identified by immunohistochemistry in a population-based patient cohort. Results Comparison of tumours relative to recurrence status revealed 121 differentially expressed genes. From this gene set, a 10-gene signature with high prognostic significance (p = 0.001) was identified and validated in an independent patient cohort (p = 0.004). Protein levels of two signature genes, HLA-DQB1 (n = 389) and LIMCH1 (LIM and calponin homology domain 1) (n = 410), were independent predictors of survival (hazard ratio 2.50, p = 0.007 for HLA-DQB1 and 3.19, p = 0.007 for LIMCH1) when adjusting for established prognostic markers. HLA-DQB1 protein expression associated with programmed death ligand 1 positivity (p < 0.001). In gene set enrichment analyses, HLA-DQB1high tumours associated with immune activation and response to interferon-γ (IFN-γ). Conclusions This study revealed a 10-gene signature with high prognostic power in cervical cancer. HLA-DQB1 and LIMCH1 are potential biomarkers guiding cervical cancer treatment.

scholarly journals Early intra-treatment diffusion weighted magnetic resonance imaging in patients with recurrent nasopharyngeal carcinoma treated with nivolumab

2020 ◽  
Vol 6 (3) ◽  
pp. 568
Author(s):  
Tiffany Y. So ◽  
Qi-Yong Ai ◽  
Brigette B.Y. Ma ◽  
Ann D. King
Keyword(s):  
Magnetic Resonance Imaging ◽  
Overall Survival ◽  
Magnetic Resonance ◽  
Nasopharyngeal Carcinoma ◽  
Progression Free Survival ◽  
Tumour Volume ◽  
Resonance Imaging ◽  
Free Survival ◽  
Diffusion Weighted ◽  
Weighted Magnetic Resonance Imaging

<p class="abstract">Immune check point inhibitors have demonstrated promising efficacy in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) in phase I and phase II trials. Early identification of treatment response is important in these patients. This report aimed to document the early intratreatment diffusion weighted magnetic resonance imaging (DW-MRI) findings in NPC patients following treatment with the programmed cell death-1 inhibitor, nivolumab. Two consecutive patients with histologically confirmed recurrent undifferentiated NPC treated with nivolumab were prospectively recruited. Nivolumab was administered at a dosage of 3 mg/kg intravenously every 2 weeks. Patients underwent magnetic resonance imaging examinations at baseline, and at 3 and 5 weeks after commencement of treatment. Intratreatment changes in tumour volume and apparent diffusion coefficient (ADC<sub>mean</sub>)were calculated. The endpoints were objective response by response evaluation criteria in solid tumors and survival. In patient 1, an intratreatment ADC increase at 5 weeks corresponded with anatomical tumour volume reduction and a better long-term survival outcome (progression free survival 1.3 years, overall survival 2.9 years). In patient 2, an intratreatment ADC decrease at 5 weeks corresponded to progressive disease and worse outcome (progression free survival 0.0 years, overall survival 0.9 years). Intratreatment ADC changes at 3 weeks were not associated with response outcome. These cases suggest that intratreatment changes in ADC at 5 weeks may potentially predict tumour response in patients treated with nivolumab. Dedicated studies are needed to clarify these findings and fully characterise patterns of treatment related ADC change.</p>

Sign in / Sign up

Export Citation Format

Share Document